Loading
A calcimimetic that lowers PTH in secondary hyperparathyroidism by sensitizing the calcium-sensing receptor.
Cinacalcet reduces PTH, calcium, and phosphorus in dialysis patients with secondary hyperparathyroidism, and is used in parathyroid cancer/hypercalcemia. Side effects include nausea and hypocalcemia — calcium must be monitored. It complements phosphate binders and vitamin D analogs in CKD-MBD management.
Overactive parathyroid glands caused by kidney failure — driven by low vitamin D, high phosphate, and low calcium — damaging bones and vessels if untreated.
Blood calcium above the normal range - in CKD usually from over-suppressed PTH, excess calcium binders, or tertiary hyperparathyroidism.
Bone disease caused by chronic kidney disease — abnormal bone turnover from calcium, phosphate, vitamin D, and PTH disturbances.
Active vitamin D (calcitriol, paricalcitol) used to control secondary hyperparathyroidism in CKD.
Advertisement
ZuvFlo is ready to integrate with your facility to streamline operations, automate compliance, and deliver better patient care.
No credit card required • Setup in under 2 hours • Cancel anytime
Advertisement
This content is a general reference, not medical advice, a diagnosis, or a treatment plan. Do not change your diet, fluids, medicines, or dialysis plan without your nephrologist or renal dietitian. Individual recommendations depend on your labs, medications, conditions, and care plan.